📢Last chance to register📢 Join Agostina Bianchi and @scherermich TOMORROW 8am PT // 17:00 CET to learn more about the Single-Cell Targeted Analysis of the Methylome (scTAM-seq) method to differentiate B cells! Register now 👉go.missionbio.com/l/552252/2023-… #dnaseq #methylation

Busy day in the Xavier Lab! Now in Cell: Results of highly collaborative work to develop a massively parallel base-editing platform for variant-to-function studies in primary cells! Broad Institute Harvard Medical School Dept. of Molecular Biology, MGH @MGH_RI sciencedirect.com/science/articl…

Delighted to have our paper, led by Jorge Diego Martin-Rufino, on conducting massively parallel base editing screens in primary human hematopoietic cells out in Cell today. Can help improve therapeutic approaches for #leukemia and #sicklecell disease: cell.com/cell/fulltext/…

We're gearing up for ASGCT #ASGCT23! Swing by Booth 820 to learn more about how Tapestri allows simultaneous measurement of genotypic and phenotypic attributes at #singlecell resolution And don't miss our posters! you can get all the details here 👉annualmeeting.asgct.org/abstracts

#SOHO2023 is around the corner! Don't miss Poster AML-481 - you'll get a peek at our new single-cell #MRD assay for heme cancers that combines targeted DNA single nucleotide and copy number mutational analysis with surface immunophenotyping Learn more👉bit.ly/3PeWH83

Interested in #MRD in #AML? Join Mission Bio at #SOHO2023 to discuss MRD Detection and Analysis with #SingleCell Resolution.

No more inference models or laborious workflows to validate Gene Editing on a single cell level. Combined Genotyping (SNV’s, CNVs, InDels, & Translocations) + Immunophenotyping (Surface Antigen Expression) in ~14,000 individual cells = 🤯

Just published in Science Advances, researchers from Memorial Sloan Kettering Cancer Center utilized the Tapestri scMRD assay to enhance MRD detection and illuminate the clonal architecture of clonal hematopoiesis/preleukemic and leukemic cells surviving #AML therapy Read more bit.ly/3LAktJl

We’re thrilled to announce the Tapestri Single-cell scMRD Multiomics AML Assay is here! Simultaneously integrate genotypic and immunophenotypic assessments of #AML #MRD to bring unprecedented clarity to disease relapse and recurrence. Learn more: bit.ly/3LBtxh2

If in Athens for #IMS23 stop by the Mission Bio poster being presented Friday afternoon P-369: Single Cell Correlation of SNVs, CNVs, and Surface Epitopes for Clonal Profiling of Myeloma

Looking for unambiguous mutational profiling in > 14,000 individual cells? Join us for our Single Cell Precision Medicine Summit in Cambridge, MA on October 30th! See you there. Registration: lnkd.in/epGXbgx4

I am thrilled to share our hot off the press paper, published in Blood Cancer Discovery today! We started by examining the role of CHIP in adult patients with ALL, and identified myeloid CH as a precursor for ALL in older adults, associated with adverse outcomes.🧵0/9 aacrjournals.org/bloodcancerdis…

Excited to have our new CEO, Brian Kim, leading Mission Bio's strategy to transition #Singlecell #Genomics to the clinic! Stay tuned as this new chapter unfolds

👋 💻🥼 Computational postdoc position in my lab ‼️ penterlab.org Come and join me! We use cutting-edge single cell and spatial approaches to develop immunotherapeutic approaches for blood cancer. #postdoc #position #datascience #immunotherapy #leukemia Please RT.

Special thanks to the Mission Bio team for coming out to interview with us at #ASGCT2024! The videos will be found here when they are published👇 cgtlive.com/conferences/am…

🚀 Last week, we announced our groundbreaking Tapestri Single-cell Multiple Myeloma Multiomics Solution! Visit our new webpage to explore how this innovation redefines addressing the complexities of MGUS, smoldering myeloma, and multiple myeloma. 🔗bit.ly/4b33R6S

#PhD in single cell #genomics to better understand clonal evolution in leukemia❓❓❓ Please consider applying for the current opening in my lab! 💡 This position is funded for three years by the DKMS. Looking forward to your application! 😊 karriere.charite.de/en/job-vacanci…

In our latest episode of On The Drop, @DruleyMB_CMO sat down with Dr. Ash Alizadeh and Dr. Mark Hamilton to discuss their latest NEJM publication, "Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy" Listen to their conversation here 👉 bit.ly/3Wpd2KU

In our latest blog, we explore the genetic diversity of multiple myeloma, and how the Tapestri Platform can help researchers gain crucial insights into the clonal heterogeneity and evolution underlying myeloma progression, therapy response, and relapse. bit.ly/3StERzq

Published today in Frontiers, researchers utilized Mission Bio's Genome Editing Solution for characterizing their triple gene-edited cell therapy, revealing heterogeneity in the combinations of on-target and off-target edits made in each cell. frontiersin.org/journals/bioen…